Stakeholders Say CMS’ 2023 MA Proposed Rule Could Go Further

Beneficiary advocates and providers argue CMS’ 2023 Medicare Advantage and Part D proposed rule doesn’t go far enough on network adequacy, plan oversight and special needs plans to support beneficiaries and rein in bad actors, but MA advocates and plans said the changes will create significant logistical burdens and unnecessary costs. Stakeholders last year eagerly watched for the Biden administration’s take on how it would handle Medicare Advantage ahead of the rule and the 2023 advanced notice and call letter...
Article Type: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 04/07/2022
CMS Volume: 
Vol. 25, No. 14
HEA Issue: 
Health Exchange Alert Weekly Report - 04/06/2022
HEA Volume: 
Vol. 10, No. 14
Author: 

Bucshon Urges E&C To Include LDT Legislation In MDUFA Discussions

Republican Rep. Larry Bucshon (IN) urged House Energy & Commerce Committee leaders to hold a hearing to discuss regulation of laboratory-developed tests and legislation to address the issue, after he chided members of the E&C health subcommittee for seeming to ignore the issue as part of their broader discussions around the reauthorization of medical device user fees. The E&C health subcommittee on Wednesday (March 30) held a hearing to discuss the MDUFA V reauthorization. Lawmakers were especially focused on artificial...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 04/08/2022
FDA Volume: 
Vol. 28, No. 14
Author: 

Providers Back Biden’s Proposed Vaccine Plan For Uninsured Adults

While hospitals and consumer advocates say the new vaccine program for uninsured adults proposed in President Joe Biden’s budget would improve access, they say it’s not a replacement for the pandemic uninsured program that’s shutting down because Congress has stalled on giving HHS additional COVID-19 relief. The pandemic program also covers costs for visits, testing and treatment services and has a broader list of eligible vaccine providers. The Biden administration’s fiscal 2023 budget released Monday (March 28) proposes not only...
Article Type: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 04/07/2022
CMS Volume: 
Vol. 25, No. 14

FDA Pulls Sotrovimab EUA In More States, Territories As BA.2 Takes Over

FDA on Wednesday (March 30) yanked emergency use authorization for GlaxoSmithKline’s COVID-19 monoclonal antibody sotrovimab in another 20 states and territories, meaning the drug is now off limits for use against coronavirus in a total of 30 states and territories where the BA.2 subvariant of Omicron has become the dominant coronavirus strain. The announcement comes as the U.S. government runs out of supply and money for COVID-19 therapies and vaccines, and as the Biden administration pushes Congress to provide immediate...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 04/01/2022
FDA Volume: 
Vol. 28, No. 13
Author: 






Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.